Across TCGA pan-cancer cohorts, IL6R Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated IL6R data layer compared with 20 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher IL6R Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IL6R expression acts as an unfavorable survival marker.
SKCM are the cancer types where IL6R Mutation most reproducibly stratifies survival.